Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features

Craig A. Magaret, Li Li, Allan C. deCamp, Morgane Rolland, Michal Juraska, Brian D. Williamson, James Ludwig, Cindy Molitor, David Benkeser, Alex Luedtke, Brian Simpkins, Fei Heng, Yanqing Sun, Lindsay N. Carpp, Hongjun Bai, Bethany L. Dearlove, Elena E. Giorgi, Mandy Jongeneelen, Boerries Brandenburg, Matthew McCallum, John E. Bowen, David Veesler, Jerald Sadoff, Glenda E. Gray, Sanne Roels, An Vandebosch, Daniel J. Stieh, Mathieu Gars, Johan Vingerhoets, Beatriz Grinsztejn, Paul A. Goepfert, Leonardo Paiva Sousa, Mayara Secco Torres Silva, Martin Casapia, Marcelo H. Losso, Susan J. Little, Aditya Gaur, Linda-Gail Bekker, Nigel Garrett, Carla Truyers, Ilse Dromme, Edith Swann, Mary A. Marovich, Dean Follmann, Kathleen M. Neuzil, Lawrence Corey, Alexander L. Greninger, Pavitra Roychoudhury, Ollivier Hyrien and Peter B. Gilbert ()
Additional contact information
Craig A. Magaret: Fred Hutchinson Cancer Center
Li Li: Fred Hutchinson Cancer Center
Allan C. deCamp: Fred Hutchinson Cancer Center
Morgane Rolland: Walter Reed Army Institute of Research
Michal Juraska: Fred Hutchinson Cancer Center
Brian D. Williamson: Fred Hutchinson Cancer Center
James Ludwig: Fred Hutchinson Cancer Center
Cindy Molitor: Fred Hutchinson Cancer Center
David Benkeser: Emory University
Alex Luedtke: University of Washington
Brian Simpkins: Pitzer College
Fei Heng: University of North Florida
Yanqing Sun: University of North Carolina at Charlotte
Lindsay N. Carpp: Fred Hutchinson Cancer Center
Hongjun Bai: Walter Reed Army Institute of Research
Bethany L. Dearlove: Walter Reed Army Institute of Research
Elena E. Giorgi: Fred Hutchinson Cancer Center
Mandy Jongeneelen: Janssen Vaccines & Prevention B.V
Boerries Brandenburg: Janssen Vaccines & Prevention B.V
Matthew McCallum: University of Washington
John E. Bowen: University of Washington
David Veesler: University of Washington
Jerald Sadoff: Janssen Vaccines & Prevention B.V
Glenda E. Gray: University of the Witwatersrand
Sanne Roels: a division of Janssen Pharmaceutica NV
An Vandebosch: a division of Janssen Pharmaceutica NV
Daniel J. Stieh: Janssen Vaccines & Prevention B.V
Mathieu Gars: Janssen Vaccines & Prevention B.V
Johan Vingerhoets: a division of Janssen Pharmaceutica NV
Beatriz Grinsztejn: Evandro Chagas National Institute of Infectious Diseases-Fundação Oswaldo Cruz
Paul A. Goepfert: University of Alabama at Birmingham
Leonardo Paiva Sousa: Evandro Chagas National Institute of Infectious Diseases-Fundação Oswaldo Cruz
Mayara Secco Torres Silva: Evandro Chagas National Institute of Infectious Diseases-Fundação Oswaldo Cruz
Martin Casapia: Universidad Nacional de la Amazonia Peru
Marcelo H. Losso: Hospital General de Agudos José María Ramos Mejia
Susan J. Little: University of California San Diego
Aditya Gaur: St. Jude Children’s Research Hospital
Linda-Gail Bekker: Observatory
Nigel Garrett: University of KwaZulu-Natal
Carla Truyers: a division of Janssen Pharmaceutica NV
Ilse Dromme: a division of Janssen Pharmaceutica NV
Edith Swann: National Institutes of Health
Mary A. Marovich: National Institutes of Health
Dean Follmann: National Institutes of Health
Kathleen M. Neuzil: University of Maryland School of Medicine
Lawrence Corey: Fred Hutchinson Cancer Center
Alexander L. Greninger: Fred Hutchinson Cancer Center
Pavitra Roychoudhury: Fred Hutchinson Cancer Center
Ollivier Hyrien: Fred Hutchinson Cancer Center
Peter B. Gilbert: Fred Hutchinson Cancer Center

Nature Communications, 2024, vol. 15, issue 1, 1-22

Abstract: Abstract In the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe–critical COVID-19. SARS-CoV-2 Spike sequences were determined from 484 vaccine and 1,067 placebo recipients who acquired COVID-19. In this set of prespecified analyses, we show that in Latin America, VE was significantly lower against Lambda vs. Reference and against Lambda vs. non-Lambda [family-wise error rate (FWER) p

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-024-46536-w Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-46536-w

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-46536-w

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().